AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Insider Transactions Reported | Ironwood Pharmaceuticals(IRWD)saw insider trading activity on 2/12/2025
ByAinvest
Wednesday, Feb 12, 2025 11:00 pm ET1min read
Ironwood Pharmaceuticals(IRWD) saw insider trading activity on 2/12/2025, there were 5 insider trades during the day.
【History Insider Transaction】
| Declare date | Position | Name | Buy/Sell | Quantity | Price per share/USD | Total Amount/USD |
|---|---|---|---|---|---|---|
| 2/12/2025 | Chief Legal Officer | John Minardo | Sell | 38938 | 1.76 | 68.53k |
| 2/12/2025 | Principal Accounting Officer | Silver Ronald | Sell | 12048 | 1.76 | 21.2k |
| 2/12/2025 | SVP, CMO, Head-Res&Drug | Shetzline Michael | Sell | 41269 | 1.76 | 72.63k |
| 2/12/2025 | Chief Financial Officer | Martini Gregory S. | Sell | 12052 | 1.76 | 21.21k |
| 2/12/2025 | Chief Executive Officer | MCCOURT Thomas A | Sell | 139064 | 1.76 | 244.75k |
| 11/20/2024 | SVP, Chief Business Officer | Davis Andrew | Sell | 5360 | 4.08 | 21.87k |
| 11/20/2024 | SVP, COO and CFO | Emany Sravan Kumar | Sell | 11001 | 4.08 | 44.88k |
| 8/14/2024 | Chief Legal Officer | John Minardo | Sell | 9910 | 4.27 | 42.32k |
| 8/14/2024 | Principal Accounting Officer | Silver Ronald | Sell | 3107 | 4.27 | 13.27k |
| 6/12/2024 | -- | McHugh Julie | Sell | 22766 | 6.29 | 143.2k |
[Company Profile]
Ironwood Pharmaceuticals, Inc. was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. Ironwood Pharmaceuticals, an S&P SmallCap 600 company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. They are pioneers in the development of LINZESS (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet